BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 8826858)

  • 1. Evaluation of phenylpiperazines as targeting agents for neuroblastoma.
    Babich JW; Graham WA; Fischman AJ
    Br J Cancer; 1996 Sep; 74(6):917-24. PubMed ID: 8826858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of adrenergic receptor ligands on metaiodobenzylguanidine uptake and storage in neuroblastoma cells.
    Babich JW; Graham W; Fischman AJ
    Eur J Nucl Med; 1997 May; 24(5):538-43. PubMed ID: 9142735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.
    Vaidyanathan G; Zhao XG; Strickland DK; Zalutsky MR
    J Nucl Med; 1997 Feb; 38(2):330-4. PubMed ID: 9025764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.
    Vaidyanathan G; Welsh PC; Vitorello KC; Snyder S; Friedman HS; Zalutsky MR
    Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1362-70. PubMed ID: 15205923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells.
    Smets LA; Loesberg C; Janssen M; Metwally EA; Huiskamp R
    Cancer Res; 1989 Jun; 49(11):2941-4. PubMed ID: 2720653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.
    Vaidyanathan G; Zhao XG; Larsen RH; Zalutsky MR
    Br J Cancer; 1997; 76(2):226-33. PubMed ID: 9231923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific uptake of m-[125I]iodobenzylguanidine in the human neuroblastoma cell line SK-N-SH.
    Buck J; Bruchelt G; Girgert R; Treuner J; Niethammer D
    Cancer Res; 1985 Dec; 45(12 Pt 1):6366-70. PubMed ID: 3864530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biology of metaiodobenzylguanidine interactions with human neuroblastoma cells.
    Iavarone A; Lasorella A; Servidei T; Riccardi R; Troncone L; Mastrangelo R
    J Nucl Biol Med (1991); 1991; 35(4):186-90. PubMed ID: 1823815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes.
    Weber W; Weber J; Senekowitsch-Schmidtke R
    Cancer Res; 1996 Dec; 56(23):5428-34. PubMed ID: 8968097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo studies with no-carrier added radioiodinated MIBG.
    Franceschini R; Pecorale A; Chinol M; Calcagni ML; Servidei T; Riccardi R; Troncone L
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):72-7. PubMed ID: 9002755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and efficacy of 131I-meta-iodobenzylguanidine in two neuroblastoma xenografts.
    Gaze MN; Hamilton TG; Mairs RJ
    Br J Radiol; 1994 Jun; 67(798):573-8. PubMed ID: 8032811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and intracellular distribution of the tumor-targeted radiopharmaceutical m-iodo-benzylguanidine in SK-N-SH neuroblastoma and PC-12 pheochromocytoma cells.
    Smets LA; Janssen M; Rutgers M; Ritzen K; Buttenhuis C
    Int J Cancer; 1991 Jun; 48(4):609-15. PubMed ID: 2045205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic effects of m-[131I]- and m-[125I]iodobenzylguanidine on the human neuroblastoma cell lines SK-N-SH and SK-N-LO.
    Bruchelt G; Girgert R; Buck J; Wolburg H; Niethammer D; Treuner J
    Cancer Res; 1988 Jun; 48(11):2993-7. PubMed ID: 3365688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG.
    Vaidyanathan G; McDougald D; Koumarianou E; Choi J; Hens M; Zalutsky MR
    Nucl Med Biol; 2015 Aug; 42(8):673-84. PubMed ID: 25956997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-iodobenzylguanidine (mIBG) uptake and storage in the human neuroblastoma cell line SK-N-BE(2C).
    Lashford LS; Hancock JP; Kemshead JT
    Int J Cancer; 1991 Jan; 47(1):105-9. PubMed ID: 1985865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.
    Mairs RJ; Russell J; Cunningham S; O'Donoghue JA; Gaze MN; Owens J; Vaidyanathan G; Zalutsky MR
    Eur J Cancer; 1995; 31A(4):576-81. PubMed ID: 7576972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Release mechanisms of [125I]meta-iodobenzylguanidine in neuroblastoma cells: evidence of a carrier-mediated efflux.
    Servidei T; Iavarone A; Lasorella A; Mastrangelo S; Riccardi R
    Eur J Cancer; 1995; 31A(4):591-5. PubMed ID: 7576975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modification of meta-iodobenzylguanidine uptake in neuroblastoma cells by elevated temperature.
    Armour A; Mairs RJ; Gaze MN; Wheldon TE
    Br J Cancer; 1994 Sep; 70(3):445-8. PubMed ID: 8080728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines.
    Strickland DK; Vaidyanathan G; Friedman HS; Zalutsky MR
    J Neurooncol; 1995; 25(1):9-17. PubMed ID: 8523094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG.
    Vaidyanathan G; Affleck DJ; Zalutsky MR
    J Nucl Med; 1995 Apr; 36(4):644-50. PubMed ID: 7699460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.